Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Chief Human Resource Officer | January 23, 2021 | January 26, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PLIANT THERAPEUTICS, INC.
Report date January 23, 2021 · Filed January 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.50 · Expires 2031-01-22 | Direct | 42,500 |
Reported balance
After 2021-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-23 · Grant · Acquired 42,500 · Balance 42,500 F1: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2021 Filed Jan 26, 2021 20:00 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (right to buy) · Derivative | 42,500 | $0.00 Strike: $26.50 | $0.00 |
DisclosureSEC source: 0000899243-21-003384 · doc4.xml · derivative · entry 1 Howes Barbara · CIK 0001809147 · Chief Human Resource Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2031-01-22 F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 21:03 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | ConversionSeries C Preferred Stock · Derivative | 27,322 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015876 · doc4.xml · derivative · entry 4 Howes Barbara · CIK 0001809147 · Chief Human Resource Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,821 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 21:03 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | ConversionCommon Stock | 3,821 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-015876 · doc4.xml · nonDerivative · entry 1 Howes Barbara · CIK 0001809147 · Chief Human Resource Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,799 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date. Read SEC document |
| March 31, 2020 Filed Jun 9, 2020 21:03 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (right to buy) · Derivative | 7,584 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0000899243-20-015876 · doc4.xml · derivative · entry 3 Howes Barbara · CIK 0001809147 · Chief Human Resource Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,584 Underlying: Common Stock · 7,584 shares Expires 2030-03-30 F2 · derivative.exercise_price: On May 22, 2020, the Issuer completed a one-for-7.15 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F2 · shares: On May 22, 2020, the Issuer completed a one-for-7.15 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F3 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date. F2 · derivative.underlying_shares: On May 22, 2020, the Issuer completed a one-for-7.15 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F2 · balance_after: On May 22, 2020, the Issuer completed a one-for-7.15 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. Read SEC document |
| February 27, 2020 Filed Jun 9, 2020 21:03 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantSeries C Preferred Stock · Derivative | 27,322 | $13.08 | $357,494.71 |
DisclosureSEC source: 0000899243-20-015876 · doc4.xml · derivative · entry 2 Howes Barbara · CIK 0001809147 · Chief Human Resource Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,322 Underlying: Common Stock · 3,821 shares Expires not disclosed F1 · derivative.exercise_price: The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date. F1 · price: The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date. F2 · price: On May 22, 2020, the Issuer completed a one-for-7.15 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F1 · derivative.exercise_date: The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date. F1 · derivative.underlying_shares: The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.